In preclinical studies, bemarituzumab inhibited FGF7-induced FGFR2 phosphorylation and the proliferation of SNU-16 cells in vitro and attenuated growth of the FGFR2-amplified GC xenografts OCUM-2M and SNU-16 in vivo. This evidence concerns the gene FGF7 and gastric cancer.